Founded by Dr. David Sugarbaker, the International Mesothelioma Program (IMP) at Brigham and Women’s Hospital is dedicated to offering cutting-edge treatment to patients suffering from malignant pleural mesothelioma, the most common form of
mesothelioma cancer. One of the largest programs of its kind in world, IMP offers clinical, research and support programs, with a clinical focus on developing treatments that can significantly extend the lives of mesothelioma patients. The program is a collaboration between Brigham and Women’s Hospital, Harvard Medical School and the Dana-Farber Cancer Institute.
Baron & Budd was a cornerstone donor and Executive Advisory Board Member of IMP.
